Related Experiment Video
Updated: May 22, 2026
03:45
Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Genotype-Phenotype Discordance in Cardiomyopathies: Pathophysiology, Clinical Expression, and Therapeutic
Abubakar Nazir1,2, Atif Hussain Sarwar3, Rameen Nazar4
1Department of Internal Medicine The Jewish Hospital-Mercy Health Ohio USA.
Health Science Reports
|May 21, 2026
Summary
Genotype-phenotype discordance in cardiomyopathies, where genetic results don't match clinical presentation, is complex. Understanding factors like epigenetics and environment is key for better diagnosis and treatment of these heart muscle disorders.
Area of Science:
- Cardiovascular Genetics
- Genomic Medicine
- Translational Cardiology
Background:
- Cardiomyopathies are myocardial disorders frequently linked to genetic mutations.
- Genotype-phenotype discordance presents significant challenges in diagnosis, prognosis, and treatment.
Purpose of the Study:
- To review mechanisms of genotype-phenotype discordance in cardiomyopathies.
- To explore clinical implications and propose future research directions.
- To bridge the gap between genetic findings and patient outcomes.
Main Methods:
- Conducted a narrative review of literature from 2000-2025 using PubMed, Scopus, and Embase.
- Searched for terms including "genotype-phenotype discordance", "cardiomyopathy", "penetrance", "expressivity", "modifier genes", and "epigenetics".
- Prioritized studies on genetic/clinical variability, penetrance, expressivity, epigenetics, polygenic, and environmental factors.
Main Results:
- Multiple factors cause discordance: incomplete penetrance, variable expressivity, epigenetics, modifier genes, and environmental influences (exercise, comorbidities).
- Discordance complicates risk stratification and personalized therapy, leading to asymptomatic carriers or unexplained disease.
- Emerging tools like polygenic risk scores and multi-omics integration aid phenotype prediction.
Conclusions:
- Genotype-phenotype discordance highlights the complexity of translating genetic data into clinical practice for cardiomyopathies.
- A multidimensional approach (genetic, molecular, environmental) is crucial for refining diagnosis, management, and genetic counseling.
- Future research needs deep phenotyping, systems biology, and longitudinal studies to understand gene-environment interactions.
Related Concept Videos
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
01:25Cardiomyopathy I: Introduction and Classification
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...